Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 204.08M P/E - EPS this Y 6.40% Ern Qtrly Grth -
Income -146.34M Forward P/E -2.01 EPS next Y 29.10% 50D Avg Chg -8.00%
Sales 140.46M PEG 0.03 EPS past 5Y - 200D Avg Chg -46.00%
Dividend N/A Price/Book N/A EPS next 5Y -30.30% 52W High Chg -70.00%
Recommedations 1.90 Quick Ratio 2.75 Shares Outstanding 124.62M 52W Low Chg 24.00%
Insider Own 9.64% ROA -31.21% Shares Float 108.36M Beta 0.21
Inst Own 62.57% ROE - Shares Shorted/Prior 21.64M/20.15M Price 1.79
Gross Margin 93.89% Profit Margin -104.18% Avg. Volume 3,435,614 Target Price 5.07
Oper. Margin -101.91% Earnings Date Jul 31 Volume 2,225,002 Change -0.56%
About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Karyopharm Therapeutics Inc. News
07/24/24 Karyopharm Therapeutics Inc. (KPTI): Is This One-Dollar Stock a Strong Buy Right Now?
07/15/24 Karyopharm Therapeutics Inc. (KPTI): Is This Penny Stock A Good Buy Right Now?
07/01/24 Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/01/24 Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
05/29/24 Karyopharm to Participate at the Jefferies Global Healthcare Conference
05/23/24 The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
05/10/24 Karyopharm Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
05/09/24 Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call Transcript
05/09/24 Karyopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
05/08/24 Q1 2024 Karyopharm Therapeutics Inc Earnings Call
05/08/24 Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript
05/08/24 Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference
05/08/24 Karyopharm Therapeutics Reports Q1 2024 Financial Results: A Detailed Review
05/08/24 Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
05/08/24 Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
05/02/24 Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024
04/24/24 Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
03/06/24 Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
03/04/24 Insider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...
03/01/24 Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript
KPTI Chatroom

User Image seforim Posted - 8 hours ago

$KPTI $INCY $GSK $MRK $AZN https://x.com/kinatsofrim/status/1816218892911665457

User Image ekpemofolo Posted - 10 hours ago

$CTXR and $KPTI While I wait for my grand plan to come to life, I am having fun trying to guess which one of these two will finish the day higher.

User Image Gius_me Posted - 11 hours ago

$KPTI green in this sea of reds meh 🫤

User Image seforim Posted - 1 day ago

$KPTI $GERN $INCY $NVS https://x.com/kinatsofrim/status/1754123089904861511

User Image seforim Posted - 1 day ago

$KPTI $GERN $INCY $NVS https://x.com/adamfeuerstein/status/1815852437783425082

User Image Argentum99 Posted - 1 day ago

$KPTI this pipeline and share price less than $1. Insane...

User Image KashkariCapital Posted - 3 days ago

$KPTI - [ ] Was the options reprice basically a “reverse options split” for employees? Making them easier to exercise at the lower price? Took in 2.14 million, replaced with 788,400. Roughly a 2.7 for 1 exchange… maybe not as bad as it seems? That means the previous contracts would only represent 37 shares rather than 100. Thoughts?

User Image celebratelife Posted - 4 days ago

$KPTI I knew the suckers would reprice the options. All incompetent management / boards do.

User Image steven1x Posted - 4 days ago

$KPTI if missed https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318459745&type=HTML&symbol=KPTI&cdn=0ea42e42ff6e58d7011126d759cf6049&companyName=Karyopharm+Therapeutics+Inc.&formType=SC+TO-I%2FA&dateFiled=2024-07-19

User Image PrettyBlob Posted - 5 days ago

$KPTI Next stop on the bottom downward trendline is low $0.70’s - put your limit buys there.

User Image seforim Posted - 5 days ago

$KPTI https://x.com/kinatsofrim/status/1814308480666202620

User Image PrettyBlob Posted - 5 days ago

$KPTI Good try, failed again. Downward trendline since March preserved perfectly. Another perfect example of mgmt failing to manage share price and take advantage of momentum. Except that PR they put out about the new orphan designations. Oh wait, they didn't do shit. unfuckingbelievable how inept these clowns are. Where are my permabulls that used to float news? Abandoned this like every other bull before because it never changes. Unless… they… Sell. The. Company.

User Image seforim Posted - 6 days ago

$KPTI $NVS $MOR $INCY This is a BIG deal for Karyopharm 🤞🏼 https://x.com/kinatsofrim/status/1813957367278760325

User Image RallyRaider Posted - 6 days ago

$KPTI Cant go places EVER???

User Image seforim Posted - 6 days ago

$KPTI $NVS $INCY $MOR https://x.com/kinatsofrim/status/1813885761424380140

User Image Gius_me Posted - 1 week ago

$KPTI I would love reading “fda agree for a early conditional approval’…meh 🫤

User Image Gius_me Posted - 1 week ago

$KPTI xbi over 100…shall we get 1 today? 🫤 meh

User Image steven1x Posted - 1 week ago

$KPTI do we have the us equivalent ? https://www.prnewswire.com/news-releases/xpovio-selinexor-approved-for-new-indication-in-dlbcl-in-china-bringing-a-new-treatment-option-to-patients-in-the-country-302190017.html

User Image steven1x Posted - 1 week ago

$KPTI listen ….he said funded last six to 8mo , but provided free from company before that https://stocktwits.com/seforim/message/579173523

User Image KashkariCapital Posted - 1 week ago

@biglouhq scroll down and check it out, also search $KPTI on reddit/x. seems like there has been a news uptick recently but its a rough outlook. very high risk, high reward possibilities if a buyout happens. not surprising situation for pharma.

User Image biglouhq Posted - 1 week ago

$KPTI any news, looking to jump in

User Image seforim Posted - 1 week ago

$KPTI https://x.com/kinatsofrim/status/1811425618183254465

User Image seforim Posted - 1 week ago

$KPTI https://x.com/kinatsofrim/status/1811417297330020589

User Image seforim Posted - 1 week ago

$KPTI https://www.nature.com/articles/s41375-024-02343-2

User Image longrigger52 Posted - 1 week ago

$KPTI $ rotating into small caps

User Image seforim Posted - 2 weeks ago

$KPTI https://x.com/kinatsofrim/status/1811056434508857790

User Image Rpjgator Posted - 2 weeks ago

$KPTI tired of holding this fucking thing.

User Image seforim Posted - 2 weeks ago

$KPTI https://x.com/kinatsofrim/status/1810847038939988074

User Image ccrowder22 Posted - 2 weeks ago

$KPTI 2 FDA Designations in the past 2 days and the CEO is selling shares the same day. I truly dont understand. Why sell at such low numbers if you want the shareholders to feel good about the stock? I’m all open to answers on good reasoning.

User Image insiderbuyingselling Posted - 2 weeks ago

$KPTI new insider selling: 3616 shares. http://insiderbuyingselling.com/?t=KPTI

Analyst Ratings
HC Wainwright & Co. Buy Jun 28, 24
HC Wainwright & Co. Buy Jun 3, 24
HC Wainwright & Co. Buy May 9, 24
HC Wainwright & Co. Buy Mar 1, 24
Piper Sandler Overweight Nov 3, 23
RBC Capital Outperform Nov 3, 23
Morgan Stanley Equal-Weight Aug 7, 23
Piper Sandler Overweight Aug 3, 23
RBC Capital Outperform Aug 3, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Paulson Richard A. President and CEO President and CEO Jan 04 Sell 0.82 4,114 3,373 783,465 01/08/24
Paulson Richard A. President and CEO President and CEO Dec 04 Sell 0.79 3,622 2,861 787,579 12/05/23
Paulson Richard A. President and CEO President and CEO Nov 06 Sell 0.9203 3,606 3,319 791,201 11/07/23
Paulson Richard A. President and CEO President and CEO Oct 04 Sell 1.27 3,589 4,558 794,807 10/05/23
BOHLIN GAREN G Director Director Sep 12 Buy 1.215 41,140 49,985 45,140 09/12/23
Paulson Richard A. President and CEO President and CEO Aug 07 Sell 1.72 3,722 6,402 802,018 08/08/23
Poulton Stuart EVP, Chief Developme.. EVP, Chief Development Officer Jul 28 Sell 1.70 2,845 4,836 156,286 08/01/23
Paulson Richard A. President and CEO President and CEO Jul 05 Sell 1.72 3,538 6,085 805,740 07/06/23
Rangwala Reshma EVP & Chief Medical.. EVP & Chief Medical Officer Apr 20 Sell 4.04 6,770 27,351 158,230 04/24/23
Paulson Richard A. President and CEO President and CEO Apr 04 Sell 3.97 3,497 13,883 816,619 04/05/23
Mason Michael EVP, CFO & Treasurer EVP, CFO & Treasurer Feb 28 Sell 3.03 11,205 33,951 245,361 03/02/23
Paulson Richard A. President and CEO President and CEO Feb 28 Sell 3.03 33,033 100,090 823,622 03/02/23
Paulson Richard A. President and CEO President and CEO Dec 05 Sell 5.17 3,490 18,043 612,527 12/06/22
Paulson Richard A. President and CEO President and CEO Nov 04 Sell 4.54 3,493 15,858 616,017 11/08/22
Paulson Richard A. President and CEO President and CEO Sep 08 Sell 5.24 3,479 18,230 622,998 09/09/22
Greene Barry E Director Director Aug 11 Option 1.485 7,576 11,250 13,606 08/15/22
Cheng Sohanya Roshan Chief Commercial Off.. Chief Commercial Officer Jun 13 Sell 5.27 1,551 8,174 89,949 06/14/22
PAKIANATHAN DEEPIKA Director Director Jun 08 Sell 6.23 538,784 3,356,624 16,673 06/10/22
Paulson Richard A. President and CEO President and CEO Jun 07 Sell 5.7602 2,542 14,642 630,906 06/08/22
Mason Michael EVP, CFO, Treasurer EVP, CFO, Treasurer Jun 03 Sell 6.05 601 3,636 138,509 06/06/22
Shacham Sharon Chief Scientific Off.. Chief Scientific Officer Feb 28 Sell 10.24 12,452 127,508 713,757 03/02/22
Kauffman Michael Director Director Feb 28 Sell 10.24 12,452 127,508 898,131 03/02/22
Kauffman Michael Director Director Feb 17 Sell 12.12 18,167 220,184 904,357 02/22/22
Shah Jatin EVP, Chief Medical O.. EVP, Chief Medical Officer Feb 07 Sell 9.862 1,704 16,805 130,756 02/09/22
Frenkel Ran EVP, Chief Dev. Offi.. EVP, Chief Dev. Officer Feb 07 Sell 9.862 1,991 19,635 104,632 02/09/22
Mason Michael EVP, CFO & Treasurer EVP, CFO & Treasurer Feb 07 Sell 9.862 3,947 38,925 53,308 02/09/22
Kauffman Michael Director Director Feb 07 Sell 9.86 13,471 132,824 913,445 02/09/22
Shacham Sharon Chief Scientific Off.. Chief Scientific Officer Feb 07 Sell 9.86 13,471 132,824 708,062 02/09/22
Shacham Sharon President & CSO President & CSO Feb 22 Sell 14.83 18,990 281,622 575,126 02/22/21
Shah Jatin EVP, Chief Medical O.. EVP, Chief Medical Officer Feb 17 Sell 15.52 1,748 27,129 48,127 02/17/21
Frenkel Ran EVP, Chief Dev. Offi.. EVP, Chief Dev. Officer Feb 17 Sell 15.52 2,046 31,754 39,338 02/17/21
Kauffman Michael Chief Executive Offi.. Chief Executive Officer Feb 17 Sell 15.52 13,243 205,531 764,147 02/17/21
Mirza Mansoor Raza Director Director Dec 22 Sell 18 5,000 90,000 12/22/20
Mirza Mansoor Raza Director Director Dec 22 Option 5.43 5,000 27,150 5,000 12/22/20
Lewis Tanya EVP,Chief Reg.&Quali.. EVP,Chief Reg.&Quality Officer Nov 04 Sell 15.58 226 3,521 539 11/04/20
Shah Jatin EVP, Chief Medical O.. EVP, Chief Medical Officer Nov 04 Sell 19.46 589 11,462 43,229 11/04/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Oct 14 Option 9.8 39,271 384,856 5,370 10/14/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Oct 14 Sell 17.03 39,271 668,785 4,649 10/14/20
Kauffman Michael Chief Executive Offi.. Chief Executive Officer Oct 14 Option 0.03 7,500 225 763,989 10/14/20
Kauffman Michael Chief Executive Offi.. Chief Executive Officer Oct 14 Sell 14.89 7,500 111,675 756,489 10/14/20
Shacham Sharon President & CSO President & CSO Oct 14 Option 0.03 7,500 225 763,989 10/14/20
Shacham Sharon President & CSO President & CSO Oct 14 Sell 14.89 7,500 111,675 756,489 10/14/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Sep 10 Option 6.54 10,054 65,753 14,703 09/10/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Sep 10 Sell 14.98 10,054 150,609 4,649 09/10/20